Aster Capital Management DIFC Ltd Grows Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Aster Capital Management DIFC Ltd raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5,482.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,745 shares of the medical equipment provider's stock after buying an additional 4,660 shares during the period. Aster Capital Management DIFC Ltd's holdings in Zimmer Biomet were worth $501,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Roman Butler Fullerton & Co. acquired a new stake in Zimmer Biomet during the 4th quarter valued at approximately $473,000. Geode Capital Management LLC increased its position in shares of Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock worth $524,942,000 after buying an additional 125,852 shares during the period. M&T Bank Corp lifted its holdings in Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock valued at $2,884,000 after buying an additional 8,709 shares during the period. KLCM Advisors Inc. bought a new stake in Zimmer Biomet during the fourth quarter valued at $7,825,000. Finally, Peddock Capital Advisors LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth about $654,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Analysts Set New Price Targets

ZBH has been the topic of a number of research reports. Raymond James dropped their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. JMP Securities reaffirmed a "market outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus increased their price target on Zimmer Biomet from $130.00 to $138.00 and gave the stock a "buy" rating in a report on Thursday, January 23rd. Finally, Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $124.15.

Remove Ads

Zimmer Biomet Price Performance

ZBH traded up $0.04 during trading on Friday, reaching $102.30. The stock had a trading volume of 2,275,065 shares, compared to its average volume of 1,629,112. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The business has a 50-day moving average of $106.31 and a 200-day moving average of $107.04. Zimmer Biomet Holdings, Inc. has a one year low of $97.69 and a one year high of $127.32. The stock has a market cap of $20.36 billion, a PE ratio of 22.99, a PEG ratio of 1.95 and a beta of 0.84.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the previous year, the firm posted $2.20 EPS. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.94%. The ex-dividend date of this dividend is Monday, March 31st. Zimmer Biomet's dividend payout ratio (DPR) is currently 21.57%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at $915,379.20. This represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.95% of the company's stock.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.